SECOND EULAR COURSE ON SYSTEMIC LUPUS ERYTHEMATOSUS San Miniato, Italy – September 4 – 9, 2005

SUNDAY 4 SEPTEMBER 2005

17.30-18.00 S. Bombardieri	Presentation of the Course
18.00-19.00 G.R.V. Hughes	Lupus in 2005. Success and failure.

MONDAY 5 SEPTEMBER 2005

Pharmacodynamics and pharmacokinetics of traditional and new drugs in SLE

8.30-8.50 M. Del Tacca 8.50-9.20 R. Danesi	Introduction Pharmacogenomics: a key for understanding drugs response in SLE
9.50-10.20 G. Ferraccioli	Pharmacogenomics and SLE: the example of Methotrexate and Azatioprine
10.20-10.50- M. Cutolo	Corticosteroids and SLE
	10.50-11.15 Break
11.15-11.45 F. Houssiau 11.45-12.15 A. Doria 12.15-12.45 P.L. Meroni	Cyclophosphamide and SLE Mycophenolate mofetil and SLE Statins, anticoagulant and antithrombotic drugs
Therapy of SLE: safety	
14.30-15.00 O. Di Munno 15.00-15.30 A.G. Tzioufas 15.30-16.00 A. Tincani	Drug therapy and osteoporosis in SLE Drug therapy and prevention of infertility in SLE Drug therapy and toxicity in pregnancy and lactation in SLE
16.00-16.30 G. Valesini	Drugs interactions in SLE

16.30- 17.00 A. Tyndall Stem cell transplantation in SLE and other autoimmune diseases

TUESDAY 6 SEPTEMBER 2005

Kidney involvement

8.30-9.00 9.00-9.30	J. Berden P. Migliorini	Role of anti-chromatin autoantibodies in the pathogenesis of lupus nephritis Other pathogenetic antibodies in lupus nephritis
Clinical pictu	re and monitoring:	
9.30-10.00 10.00-10.30		Histological and clinical features of lupus nephritis Optimizing the clinical monitoring of lupus nephritis and evaluation of prognostic factors in lupus nephritis

	1 0	
10.30-11.00 D. Boumpas	Therapeutic algorhytms in lupus	nephritis

11.00-11.30 Break

11.30-13.00 Discussion of clinical cases

Particular issues

14.30-15.00	M.A. Khamashta	Pregnancy and SLE
15.00-15.30	F. Conti	Vaccination in SLE
15.30-16.00	C.M. Montecucco	Fever and SLE
16.00-16.30	M. Mosca	Undifferentiated connective tissue diseases

WEDNESDAY 7 SEPTEMBER 2005

CNS involvement

8.30-9.00	G. Riemekasten	Pathogenesis of	central	nervous	system	involvement i	n
		SLE					

Clinical pictures:

9.00-9.30	J.C. Piette	Neurological manifestations of CNS involvement in SLE
9.30-10.00	D. D'Cruz:	Fatigue and psychiatric manifestations in SLE.
10.00-10.30	M. Govoni:	Optimizing the diagnosis and the clinical monitoring of CNS involvement in SLE
10.30-11.00	T. Huizinga:	Therapeutic algorhytms of neurological involvement in SLE.

11.00-11.30 Break

11.30-13.00 Discussion of clinical cases

Afternoon : FREE

THURSDAY 8 SEPTEMBER 2005

Therapy of SLE: From bench to the bedside

9.00-10.00 J. Kalden:	Pathogenesis as a clue for targeted therapies for S		
10.00-10.30 M. Aringer	Prospects of biological therapies in SLE		
10.30-11.00 J.S. Smolen	Rituximab, CTLA4-Ig and peptide treatment in SLE		
	11.00-11.30 Break		
11.30-12.00 M. Galeazzi	Causes of death in SLE		
12.00-12.45 R.J.T. Smeenk	Autoantibodies in clinical practice in SLE patients		

Skin manifestation

14.30-15.00 R. Rondinone:	Diagnosis	and	differential	diagnosis	of	cutaneous
	involvemen	t in SL	.E			
15.00-15.30 A. Kuhn:	Treatment	of cuta	ineous involv	ement in SL	E	

15.30-17.00 Discussion of clinical cases

FRIDAY 9 SEPTEMBER 2005

Measures to assess and monitoring a patient with SLE and response to therapy: creation of a data base for SLE patients

Gordon Schneider Manger	The evaluation of patients with SLE The assessment of quality of life in SLE Development of a responder Index for SLE Diagnostic factors The core set variables to monitor patients with SLE
	11.00-11.30 Break
0	

11.30-12.00 R. Cervera:	Haematological manifestations of SLE
12.00-12.45 Y. Shoenfeld	Atherosclerosis and autoimmunity: the example of SLE

Afternoon

14.30-15.00 Report of the results of a questionnaire on renal involvement15.00-15.30 Report of the results of a questionnaire on cutaneous involvement15.30-16.00 Report of the results of a questionnaire on neurological involvement

Credits and departures